WallStreetZenWallStreetZen

NASDAQ: HRTX
Heron Therapeutics Inc Stock

$1.49+0.08 (+5.67%)
Updated Dec 8, 2023
HRTX Price
$1.49
Fair Value Price
$1.72
Market Cap
$223.61M
52 Week Low
$0.50
52 Week High
$3.41
P/E
-1.62x
P/B
-8.05x
P/S
1.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$122.84M
Earnings
-$119.70M
Gross Margin
44.8%
Operating Margin
-96.77%
Profit Margin
-97.4%
Debt to Equity
-9.25
Operating Cash Flow
-$99M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HRTX Overview

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HRTX ($1.49) is undervalued by 13.23% relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HRTX ($1.49) is not significantly undervalued (13.23%) relative to our estimate of its Fair Value price of $1.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HRTX due diligence checks available for Premium users.

Be the first to know about important HRTX news, forecast changes, insider trades & much more!

HRTX News

Valuation

HRTX fair value

Fair Value of HRTX stock based on Discounted Cash Flow (DCF)
Price
$1.49
Fair Value
$1.72
Undervalued by
13.23%
HRTX ($1.49) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HRTX ($1.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HRTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.62x
Industry
11.7x
Market
31.32x

HRTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-8.05x
Industry
5.42x

HRTX's financial health

Profit margin

Revenue
$31.4M
Net Income
-$25.0M
Profit Margin
-79.6%
HRTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HRTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$229.2M
Liabilities
$257.0M
Debt to equity
-9.25
HRTX's short-term assets ($193.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HRTX's short-term assets ($193.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.2M
Investing
-$23.2M
Financing
$53.8M
HRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HRTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
HRTX$223.61M+5.67%-1.62x-8.05x
AEON$224.44M-0.66%10.60x-1.84x
QSI$222.51M+1.29%-2.07x0.76x
CMPX$221.83M+0.58%-5.27x1.39x
FATE$220.87M-4.68%-1.27x0.55x

Heron Therapeutics Stock FAQ

What is Heron Therapeutics's quote symbol?

(NASDAQ: HRTX) Heron Therapeutics trades on the NASDAQ under the ticker symbol HRTX. Heron Therapeutics stock quotes can also be displayed as NASDAQ: HRTX.

If you're new to stock investing, here's how to buy Heron Therapeutics stock.

What is the 52 week high and low for Heron Therapeutics (NASDAQ: HRTX)?

(NASDAQ: HRTX) Heron Therapeutics's 52-week high was $3.41, and its 52-week low was $0.50. It is currently -56.3% from its 52-week high and 198% from its 52-week low.

How much is Heron Therapeutics stock worth today?

(NASDAQ: HRTX) Heron Therapeutics currently has 150,072,640 outstanding shares. With Heron Therapeutics stock trading at $1.49 per share, the total value of Heron Therapeutics stock (market capitalization) is $223.61M.

Heron Therapeutics stock was originally listed at a price of $530.00 in Dec 31, 1997. If you had invested in Heron Therapeutics stock at $530.00, your return over the last 25 years would have been -99.72%, for an annualized return of -20.94% (not including any dividends or dividend reinvestments).

How much is Heron Therapeutics's stock price per share?

(NASDAQ: HRTX) Heron Therapeutics stock price per share is $1.49 today (as of Dec 8, 2023).

What is Heron Therapeutics's Market Cap?

(NASDAQ: HRTX) Heron Therapeutics's market cap is $223.61M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Heron Therapeutics's market cap is calculated by multiplying HRTX's current stock price of $1.49 by HRTX's total outstanding shares of 150,072,640.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.